Caris Life Sciences (CAI) Enterprise Value (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Enterprise Value of -$823.5 million for Q1 2026, down 2.92% quarter-over-quarter from -$800.1 million in Q4 2025.
Caris Life Sciences (CAI) Enterprise Value (2024 - 2026) Analysis & Trends
Caris Life Sciences' Enterprise Value history runs 3 years deep, the most recent figure standing at -$823.5 million for Q1 2026.
- In Q1 2026, Enterprise Value changed N/A year-over-year to -$823.5 million; the TTM figure through Mar 2026 stood at -$823.5 million (changed N/A YoY), while the FY2025 annual figure was -$800.1 million, down 1082.82% from the prior year.
- Enterprise Value for Q1 2026 stood at -$823.5 million, down from -$800.1 million in the prior quarter.
- The five-year high for Enterprise Value was -$67.6 million in Q4 2024, with the low at -$823.5 million in Q1 2026.
- The 3-year median for Enterprise Value is -$757.0 million (2025), against an average of -$634.0 million.
- Peak annual rise in Enterprise Value reached 1082.82% in 2025, while the deepest fall reached 1082.82% in 2025.
- Caris Life Sciences' Enterprise Value stood at -$67.6 million in 2024, then sank by 1082.82% to -$800.1 million in 2025, then decreased by 2.92% to -$823.5 million in 2026.
- Business Quant data shows CAI's Enterprise Value at -$823.5 million in Q1 2026, -$800.1 million in Q4 2025, and -$757.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | -793.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -793.12 Mn |
| Mar 31, 2026 | -823.46 Mn |
| Dec 31, 2025 | -800.09 Mn |
| Sep 30, 2025 | -757.01 Mn |
| Jun 30, 2025 | -721.95 Mn |
| Dec 31, 2024 | -67.64 Mn |